文献速递静脉血栓栓塞慢性静脉疾病

经皮机械血栓清除术治疗下肢深静脉血栓的荟萃分析与系统评价

Meta-analysis and systematic review of percutaneous mechanical thrombectomy for lower extremity deep vein thrombosis.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2018-01-01

该系统评价检索PubMed截至2017年3月2日的文献,纳入35项研究共1323例接受经皮机械血栓清除术(PMT)±导管接触性溶栓(CDT)的下肢深静脉血栓患者,汇总分析围术期与长期结局。PMT±CDT部分溶栓率93.4%、完全溶栓率67.0%,30天再血栓率11.9%、DVT相关死亡率2.4%,围术期大出血4.6%、肺栓塞3.8%。与单纯CDT比较的6项研究显示PMT±CDT部分溶栓率更高(OR 2.64),溶栓药物剂量更低、手术时间更短,大出血与肺栓塞无显著差异。

要点

  • PMT±CDT部分溶栓率93.4%(95%CI 90.1%-95.6%),完全溶栓率67.0%(95%CI 59.1%-76.4%)。
  • 30天再血栓率11.9%(95%CI 6.7%-20.3%),30天DVT相关死亡率2.4%(95%CI 1.6%-3.7%)。
  • 与单纯CDT比,PMT±CDT部分溶栓率更高(OR 2.64,95%CI 1.34-5.21,P=.005)。

核心结论

  • 作者认为,PMT±CDT因围术期并发症发生率可接受且短期或长期结局令人满意,是下肢DVT患者相对有效且安全的方法。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed截至2017年3月2日发表的临床试验及前瞻性或回顾性病例系列(比较性或单臂研究),聚焦PMT±CDT治疗DVT。
  • 共纳入35项研究、1323例PMT±CDT患者。
  • 比较PMT±CDT与单纯CDT的分析纳入6项研究,PMT±CDT组195例、CDT组193例。

主要发现

  • PMT±CDT患者部分溶栓率93.4%(95%CI 90.1%-95.6%),完全溶栓率67.0%(95%CI 59.1%-76.4%)。
  • 30天再血栓率11.9%(95%CI 6.7%-20.3%),30天DVT相关死亡率2.4%(95%CI 1.6%-3.7%)。
  • 围术期大出血发生率4.6%(95%CI 2.9%-7.3%),肺栓塞发生率3.8%(95%CI 2.5%-6.7%)。
  • 随访期间晚期再血栓率10.7%(95%CI 8.7%-13.0%;平均随访期2.8至32.1个月),15.1%(95%CI 9.6%-22.9%)发生血栓后综合征(平均随访期3.8至29.6个月)。
  • 与单纯CDT相比,PMT±CDT组部分溶栓率更高(OR 2.64,95%CI 1.34-5.21,P=.005),完全溶栓率无显著差异(OR 1.38,95%CI 0.87-2.18,P=.17)。

关键数值与推荐

  • 两组随访期间Villalta评分差异无统计学意义(OR -0.50,95%CI -1.34至0.34,P=.24)。
  • PMT±CDT组溶栓药物剂量低于CDT组(标准均数差 -0.98,95%CI -1.59至-0.38,P=.001),手术时间更短(均数差 -16.94,95%CI -22.38至-11.50,P<.00,001)。
  • 两组大出血(OR 1.20,95%CI 0.50-2.90,P=.24)与肺栓塞(OR 1.18,95%CI 0.16-8.73,P=.87)无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this review was to evaluate the efficacy and safety of percutaneous mechanical thrombectomy (PMT) with or without catheter-directed thrombolysis (CDT) in the treatment of lower extremity deep venous thrombosis (DVT). METHODS: We searched PubMed for clinical trials and prospective or retrospective case series (comparative or single-arm studies) that focused on PMT ± CDT in the treatment of DVT, published before March 2, 2017. We meta-analyzed perioperative outcomes and complications and long-term outcomes of this procedure. We also compared the results between PMT ± CDT and CDT alone, using the data from comparative studies. RESULTS: Overall, 1323 PMT ± CDT patients from 35 studies were included in our study. The rate of patients experiencing successful thrombolysis with a partial or complete lysis rate was 93.4% (95% confidence interval [CI], 90.1%-95.6%) or 67.0% (95% CI, 59.1%-76.4%), respectively. The pooled proportion of 30-day rethrombosis rate was 11.9% (95% CI, 6.7%-20.3%). The 30-day DVT-related mortality was 2.4% (95% CI, 1.6%-3.7%). The perioperative incidence of major bleeding and pulmonary embolism was 4.6% (95% CI, 2.9%-7.3%) and 3.8% (95% CI, 2.5%-6.7%), respectively. During the follow-up, the late rethrombosis rate was 10.7% (95% CI, 8.7%-13.0%; the average follow-up period ranged from 2.8 to 32.1 months). About 15.1% (95% CI, 9.6%-22.9%) of patients developed post-thrombotic syndrome during follow-up (the average follow-up period varied from 3.8 to 29.6 months). In comparing the results of PMT ± CDT with CDT alone, six studies were included (195 patients in the PMT ± CDT group and 193 patients in the CDT group). The partial thrombolysis rate was higher in the PMT ± CDT group (odds ratio [OR], 2.64; 95% CI, 1.34-5.21; P = .005), whereas the complete lysis rate was not (OR, 1.38; 95% CI, 0.87-2.18; P = .17). The difference between the Villalta scores of the two groups during follow-up had no statistical significance (OR, -0.50; 95% CI, -1.34 to 0.34; P = .24). The thrombolytic drug dose in the PMT ± CDT group was much lower than that in the CDT group (standard mean difference, -0.98; 95% CI, -1.59 to -0.38; P = .001), and the procedural time was shorter in the PMT ± CDT group (mean difference, -16.94; 95% CI, -22.38 to -11.50; P < .00,001). There was no significant difference in major bleeding (OR, 1.20; 95% CI, 0.50-2.90; P = .24) or pulmonary embolism (OR, 1.18; 95% CI, 0.16-8.73; P = .87) between the two groups. CONCLUSIONS: PMT with or without CDT is a relatively effective and safe approach for lower extremity DVT patients because of the acceptable incidence of perioperative complications and satisfying short- or long-term outcomes.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Wang W, Sun R, Chen Y, et al. Meta-analysis and systematic review of percutaneous mechanical thrombectomy for lower extremity deep vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2018. PMID: 30336908. doi:10.1016/j.jvsv.2018.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。